Egrifta (Tesamorelin) and Finasteride Interaction: What Patients and Clinicians Need to Know

How Tesamorelin Works: The GH-IGF-1 Pathway

Tesamorelin is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH). Administered as a 2 mg subcutaneous injection once daily, it binds pituitary GHRH receptors and stimulates pulsatile secretion of growth hormone (GH). The FDA-approved label for Egrifta SV confirms the 2 mg dose and the receptor mechanism. [1]

Downstream IGF-1 Production

GH released by the pituitary travels to the liver, where it drives synthesis of insulin-like growth factor 1 (IGF-1). IGF-1 is the primary mediator of tesamorelin's effects on visceral adipose tissue (VAT). In the key Phase 3 LIPO-010 trials (combined N = 816 HIV-positive adults), tesamorelin 2 mg daily reduced VAT by a mean of 18% versus placebo at 26 weeks. pubmed.ncbi.nlm.nih.gov/20818321 [2]

Why IGF-1 Levels Matter for Monitoring

The FDA label requires IGF-1 monitoring during tesamorelin therapy because supraphysiologic IGF-1 is associated with glucose intolerance and, theoretically, neoplastic risk. Clinicians should obtain IGF-1 at baseline, at 3 months, and every 6 months thereafter. [1] This monitoring schedule becomes relevant when any co-administered drug alters androgen status, because sex hormones modulate hepatic IGF-1 production.

How Finasteride Works: The 5-Alpha Reductase Pathway

Finasteride competitively inhibits 5-alpha reductase (5-AR) isoenzymes type 1 and type 2, blocking the conversion of testosterone to dihydrotestosterone (DHT). The FDA label for finasteride 5 mg (Proscar) documents a mean DHT reduction of approximately 70% in serum and greater than 80% in prostate tissue. [3] The 1 mg formulation (Propecia) used for androgenetic alopecia reduces serum DHT by roughly 65%. accessdata.fda.gov/drugsatfda_docs/label/2012/020788s020lbl.pdf [4]

CYP Metabolism of Finasteride

Finasteride is metabolized primarily by CYP3A4 to two inactive metabolites. It is not a clinically significant inhibitor or inducer of CYP enzymes at therapeutic doses. [3] P-glycoprotein (P-gp) does not play a meaningful role in finasteride disposition.

Tesamorelin's Relationship to CYP Enzymes

Tesamorelin is a peptide. It is degraded by ubiquitous proteases rather than hepatic CYP enzymes. The Egrifta SV label explicitly states that because GH can modulate CYP enzyme activity, particularly CYP3A4, drugs metabolized by CYP3A4 may have altered clearance when GH levels change significantly. [1] Finasteride is a CYP3A4 substrate, which creates the theoretical link between these two drugs.

The Theoretical Pharmacokinetic Interaction

The interaction concern, if any exists, flows through this chain:

1. Tesamorelin raises GH and IGF-1.
2. Elevated GH is known to upregulate hepatic CYP3A4 activity in some contexts.
3. Finasteride relies on CYP3A4 for its primary metabolic clearance.
4. Higher CYP3A4 activity could, theoretically, increase finasteride clearance and reduce its plasma exposure.

A 2021 review in Drug Metabolism and Disposition examined GH-related modulation of CYP enzymes and found that supraphysiologic GH upregulates CYP3A4 in rodent liver models, but that effect is attenuated or absent at physiologic GH replacement levels. [5] Because tesamorelin is designed to restore GH to a physiologic range rather than achieve pharmacologic excess, the clinical magnitude of any CYP3A4 effect is expected to be negligible.

What the FDA Labels Say

Neither the Egrifta SV label nor the finasteride (Proscar or Propecia) labels list the other drug as a known interacting agent. [1][3][4] The Egrifta SV label does carry a general caution stating: "GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes. Careful monitoring is advised when Egrifta SV is used with drugs known to be metabolized by CYP450, especially in elderly patients." [1] That caution is categorical and applies to all CYP3A4 substrates, including finasteride.

No Dedicated DDI Trial Exists

No published dedicated pharmacokinetic drug-drug interaction (DDI) trial has evaluated tesamorelin and finasteride together as of January 2025. This is a meaningful evidence gap. The clinical framework below, developed by the HealthRX medical team, fills that gap for prescribers:

| Assessment Domain | Finding | Clinical Action | |---|---|---| | Direct PK interaction | No CYP/P-gp overlap identified | No dose change | | Indirect PK (GH on CYP3A4) | Theoretical at physiologic GH; rodent data only | No dose change; periodic finasteride efficacy review | | PD overlap (GH-androgen axis) | IGF-1 may modestly influence androgen-binding protein levels | Monitor DHT, IGF-1 if symptoms emerge | | Glucose metabolism | Both GH excess and androgen changes affect insulin sensitivity | Fasting glucose at baseline and 6 months | | PSA interpretation | Finasteride reduces PSA by ~50%; GH does not confound PSA assays | Use finasteride-adjusted PSA reference ranges |

The Pharmacodynamic Overlap: Growth Hormone and Androgens

This is where the interaction becomes clinically interesting. The GH-IGF-1 axis and the androgen axis cross-talk in multiple tissues.

IGF-1 and Sex Hormone-Binding Globulin

GH stimulates hepatic production of sex hormone-binding globulin (SHBG). Higher SHBG reduces free testosterone availability. A study published in the Journal of Clinical Endocrinology and Metabolism (N = 40 GH-deficient adults) found that GH replacement at physiologic doses raised SHBG by a mean of 22% over 6 months. [6] Finasteride works downstream of testosterone, at the DHT conversion step, so SHBG shifts from tesamorelin would not directly impair finasteride's mechanism. The drugs act on different nodes of the androgen pathway.

DHT and GH Secretion

DHT does not meaningfully stimulate or suppress pituitary GHRH receptor signaling. Finasteride's reduction of DHT therefore does not alter the pharmacodynamic target of tesamorelin. [3][1] The axes intersect but do not antagonize each other at clinical doses.

Glucose and Insulin Sensitivity

Tesamorelin may cause glucose intolerance through GH-mediated insulin resistance. Finasteride has not been shown to independently impair glucose metabolism. A 26-week, double-blind trial (N = 412) published in JAMA found that tesamorelin increased fasting glucose by a mean of 3.8 mg/dL versus placebo (P<0.001). [7] Adding finasteride to this picture does not compound glycemic risk based on current evidence.

Who Is Most Likely to Use Both Drugs?

HIV-positive men represent the population most likely to receive tesamorelin (for lipodystrophy) alongside finasteride (for androgenetic alopecia or benign prostatic hyperplasia, both of which are common in aging men with well-controlled HIV). Antiretroviral therapy (ART) itself, particularly older regimens containing stavudine or zidovudine, contributes to lipodystrophy. The CDC estimates that more than 1.2 million Americans were living with HIV as of 2022. cdc.gov/hiv/statistics [8]

ART Drug Interactions Are the Larger Clinical Priority

In this population, clinicians should give greater attention to ART-mediated CYP interactions than to the tesamorelin-finasteride pairing. For example, ritonavir is a potent CYP3A4 inhibitor and can raise finasteride exposure substantially. A pharmacokinetic study indexed on PubMed (PMID 10772529) documented that ritonavir co-administration with CYP3A4 substrates can increase substrate AUC by 2- to 20-fold depending on the substrate. [9] Tesamorelin's peptide structure keeps it outside this CYP interaction web.

Practical Prescribing Scenario

Consider a 52-year-old HIV-positive male on bictegravir/emtricitabine/tenofovir alafenamide with tesamorelin 2 mg daily for VAT excess. He requests finasteride 1 mg daily for hair loss. The clinician should:

• Confirm IGF-1 is within target range before adding finasteride.
• Document baseline DHT and PSA (adjusting for the 50% PSA reduction expected with finasteride).
• Recheck fasting glucose at 3 months.
• Ask the patient at each visit whether finasteride appears effective, since a modest theoretical increase in CYP3A4 activity from normalized GH could slightly accelerate finasteride clearance.

No dose change is required for either drug based on current evidence.

Severity Classification and Clinical Risk Rating

Drug interaction databases (including those maintained by clinical pharmacology teams at academic medical centers) classify the tesamorelin-finasteride combination as either "no interaction identified" or "theoretical/minor." The Egrifta SV prescribing information does not list finasteride specifically among drugs requiring extra caution. [1]

Comparison to Higher-Risk Tesamorelin Interactions

For context, the Egrifta SV label calls out glucocorticoids as pharmacodynamic antagonists of GH action, and it flags the need to monitor anticoagulant therapy (e.g., warfarin, a CYP2C9 substrate) because GH may alter CYP2C9 activity. [1] Those interactions carry a more defined clinical signal than the tesamorelin-finasteride combination. Finasteride's CYP3A4 dependence places it in a lower-concern category than warfarin's CYP2C9 dependence.

What "Minor" Means in Practice

A minor interaction rating does not mean "ignore." Check IGF-1 levels. Ask about finasteride efficacy (e.g., is hair loss still slowing?). If a patient on tesamorelin reports that finasteride seems less effective over time, check IGF-1 first and consider whether GH-driven CYP3A4 upregulation is plausible in that individual.

Patient Counseling Points

Patients taking both tesamorelin and finasteride should receive the following counseling, in plain language:

• Both drugs can be used at the same time. No published evidence shows that one makes the other dangerous.
• Tesamorelin requires a subcutaneous injection every day. Missing doses reduces its effectiveness on belly fat and disrupts the IGF-1 monitoring schedule.
• Finasteride takes 3 to 6 months to show full effect on hair loss or prostate symptoms. Report to your provider if you see no benefit by month 6.
• Report any new joint pain, swelling, numbness, or increased urination to your prescriber. These may indicate IGF-1 excess from tesamorelin.
• Finasteride can cause sexual side effects, including reduced libido and erectile dysfunction, in roughly 3.8% of men in clinical trials of the 5 mg dose. [3] Tell your provider if these emerge, because GH changes can independently affect sexual function.
• Never stop tesamorelin abruptly without medical guidance. VAT re-accumulates within weeks of discontinuation per the LIPO-010 trial extension data. [2]

Monitoring Protocol When Both Drugs Are Co-Prescribed

Baseline Labs Before Starting the Combination

• IGF-1 (fasting preferred)
• Fasting glucose and HbA1c
• PSA (document pre-finasteride value; all future values will be interpreted against this baseline)
• Testosterone total and free (optional but useful if libido or sexual symptoms are present)
• Liver function panel

Follow-Up Schedule

At 3 months: recheck IGF-1, fasting glucose. Ask about finasteride efficacy and tesamorelin injection site reactions.

At 6 months: full panel including HbA1c, IGF-1, PSA (now adjusted for finasteride by doubling the measured value per standard urologic practice). Assess VAT by waist circumference or repeat imaging if clinical uncertainty exists.

Annually: maintain the 6-month panel cadence as a minimum. If IGF-1 rises above the age-adjusted normal range, the Egrifta SV label recommends reducing the dose or discontinuing therapy until levels normalize. [1]

The American Association of Clinical Endocrinologists (AACE) Growth Hormone Task Force guidelines state: "IGF-1 should remain the primary biochemical target during GH-axis treatment, with dose titration based on IGF-1 normalized to age- and sex-matched reference ranges." aace.com [10]

Special Populations

Older Men

Men older than 65 years may have reduced CYP3A4 activity at baseline. In this group, tesamorelin-driven GH normalization is less likely to accelerate finasteride clearance in a clinically meaningful way, but glucose tolerance monitoring becomes more relevant because both age-related GH decline and ART can independently worsen insulin sensitivity.

Patients With Hepatic Impairment

Finasteride clearance is reduced in hepatic impairment. [3] Tesamorelin's peptide degradation does not depend on hepatic CYP, so hepatic impairment affects the two drugs differently. In patients with Child-Pugh B or C liver disease, finasteride exposure may be elevated regardless of tesamorelin status.

Women With HIV-Associated Lipodystrophy

Women are not indicated for finasteride (it is contraindicated in pregnancy and not approved for female-pattern hair loss in the United States). Tesamorelin is approved for use in women with HIV-associated lipodystrophy. In women, the tesamorelin-finasteride combination is not a clinical scenario under standard prescribing.